Punching above their weight, Predictmedix keeps nailing the heavyweight health tech partnerships

As the world shifts to a “new” normal, employee and customer screenings will be commonplace and Predictmedix Inc. (CSE: PMED | OTCQB: PMEDF) and its solutions are leading the way.

The recent announcement by Predictmedix, regarding the partnership with McGill University, is another example of the relationships that Dr. Rahul Kushwah, COO of Predictmedix, is developing with major corporations and leading healthcare providers as it rolls out Artificial Intelligence (“AI”) health tech solutions.

Predictmedix aims to improve the healthcare system through innovative and cutting-edge digital health technologies. Currently, Predictmedix AI solutions focus on infectious-disease screenings, impairment detection, and remote patient monitoring.

The Company’s products use facial, thermal, video, and audio recognition technologies to determine when individuals are impaired, suffering from an infectious disease, or mental illness. One solution focuses on mass and rapid AI-based screening for COVID-19 symptoms.

Partnerships, Pilots, Trials and Installs – Where Does Predictmedix Find the Time

Earlier this month, Predictmedix announced partnering with a research group led by Dr. Samira Rahimi from McGill University’s Department of Family Medicine.

Dr. Rahimi’s research group will be working with Predictmedix and its three industry verticals:  (1) screening for infectious disease associated symptoms; (2) screening for alcohol or cannabis impairment; and, (3) mental health screening.

Dr. Rahul Kushwah commented, “We are extremely excited with the partnership with Dr. Samira Rahimi’s team. Dr. Rahimi is one of the most recognized AI – healthcare scientists in Canada and we look forward to with her and her research team for our 3 major verticals.”

The announcement with McGill is just the latest in a series of pilot projects, partnerships, and product rollouts that Predictmedix has successfully executed this year. Predictmedix believes that it is well-positioned for growth and to capture the current sales momentum into Q1/2021.

Recently, the Company announced that it will be deploying its COVID-19 screening technology along with alcohol and impairment screening technology at Indian Oil Corporation Ltd (NSE:IOC.NS), a multi-billion dollar India-based oil company, and the deployment of its mass screening technology for COVID-19 with Max Healthcare, one of the largest healthcare groups in South Asia, encompassing 14 hospitals with over 3000 doctors.

Predictmedix also announced a collaboration with India-tech giant Tech Mahindra Ltd (NSE: TECHM), to incorporate Predictmedix’s impairment detection technology and COVID-19 solutions into Tech Mahindra’s suite of technologies offered for workplace health and safety across the globe.

Closer to home, the Company, in conjunction with its partner Juiceworks Exhibits, successfully deployed its infectious disease screening technology at Flow Water in Aurora, Ontario, and a 24-hour pharmacy in Montreal, Quebec.

Used by employees on a daily basis, Predictmedix’s gateway screens individuals, in a non-invasive way, as they walk through and it triggers an alarm if symptoms associated with an infectious disease are detected, such as COVID-19, or signs of impairment due to alcohol or cannabis use.

The screening product consists of hardware, software, multi-spectral cameras, and specialized sensors that are assembled into a gateway, much like a metal detector in an airport, and communicates with Predictmedix’s AI model in the cloud.

Remote Patient Monitoring & Telehealth Enterprise Platform with Mobile Wellbeing Acquisition

In June, Predictmedix acquired Mobile Wellbeing, a remote patient monitoring platform, which is strategic for the Company in creating an enterprise platform and allows Predictmedix to enter the telehealth and clinical trials markets.

According to a recent by study Adroit Market Research, the Remote Patient Monitoring Market is anticipated to reach US$1.9 billion by 2026, growing at a CAGR of almost 13% from 2020 to 2026.

With current stay-at-home orders due to the COVID-19 health crisis, clinical drug trials shifted to remote monitoring from on-site monitoring. The U.S. Food and Drug Administration (“FDA”) now supports remote monitoring for oversight of clinical sites.

In addition, the Mobile Wellbeing platform is equally suited for use in long-term care facilities to care for elderly patients. Big Data features include assisted monitoring that allows for data collection, transmission, evaluation, and notification. Utilizing the latest off-the-shelf wearables, the platform has shown benefits such as improved patient health and also lowered the cost of care through remote monitoring.

Predictmedix anticipates the commercial launch of its remote patient monitoring platform Q1/2021 with some key, large-scale deployments in North America and Asia.

Predictmedix is currently trading at $0.46 with a market cap of $46.5M but with billion-dollar partners and a pipeline of projects in Q1/2021, clearly ready for a re-rating.

Dr. Rahul Kushwah on Predictmedix’s remote patient monitoring technology and Mobile Wellbeing

In a recent InvestorIntel interview, Tracy Weslosky speaks with Dr. Rahul Kushwah, Co-Founder and COO of Predictmedix Inc. (CSE: PMED | OTCQB: PMEDF), about their infectious disease screening technology and remote patient monitoring platform, Mobile Wellbeing.

In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Dr. Kushwah talked about the successful North American deployment of Predictmedix’s infectious disease screening technology at Flow Water in Aurora, Ontario. Dr. Kushwah went on to provide an update on their Mobile Wellbeing platform. “It is in telehealth and telemedicine business, but it does more than that.” He continued, “It does something which is referred to as remote patient monitoring.” Dr. Kushwah added that Predictmedix is targeting clinical trials and long-term care markets with its Mobile Wellbeing platform. FDA now has very strong guidance which is promoting remote patient monitoring and that brings Predictmedix’s technology to the forefront.

In the interview Dr. Kushwah also said that Accenture, a multinational professional services company and a Fortune Global 500 company, recently wrote about how Predictmedix is innovating to help with the current COVID-19 pandemic (click here to read the article). “It should indicate to shareholders that not only our technology is disruptive but we are clearly in a market segment which is not only ballooning right now but is going to be huge as time goes by.” Dr. Kushwah commented. To watch the full interview, click here

About Predictmedix

Predictmedix develops AI technologies focused on areas which include screening for impairment, infectious disease and mental health, and a remote patient monitoring/telehealth platform, all of which play a vital role in health and safety. Their technologies are timely to assist with the current pandemic, as well as having lasting utility that goes beyond the current crisis, extending into workplace health, safety and compliance.

To learn more about Predictmedix Inc., click here

Disclaimer: Predictmedix Inc. is an advertorial member of InvestorIntel Corp.

Diagnos’ AI Platform to Fight Vision Loss Continues to Expand Globally

Diagnos Inc. (TSXV: ADK | OTCQB: DGNOF) is a software platform provider for the early detection of critical health issues through the use of Artificial Intelligence (“AI”) and Machine Learning (“ML”), and it continues to expand globally with recent deals and government financing support.

Utilizing AI and ML, Diagnos developed a Computer Assisted Retina Analysis (“CARA”) software platform to process image data, making standard retinal images sharper, clearer, and easier to read. This technology assists healthcare specialists in the detection of vision loss, including diabetic retinopathy.

CARA is a teleophthalmology platform, a branch of telemedicine, which delivers eye care through digital medical equipment and telecommunications technology. The CARA platform integrates with various types of existing retinal cameras at the point of care, is compatible with all recognized image formats, and is Electronic Medical Records (“EMR”) compatible.

Digital Health Surging

AI technology is spreading rapidly into various verticals including automotive, healthcare, and pharmaceuticals. According to ABI Research, global AI venture capital investments in the healthcare and pharmaceutical sectors reached $2.4 billion in 2019, up 140%, compared with $1 billion in the prior year.

In the healthcare industry, companies are leveraging AI to overcome human’s lack of ability to detect pertinent details in data from various sources, including photos, microscopic images, X-rays, CT scans, and MRI scans.

During the current COVID-19 health crisis, with shelter-at-home orders, telemedicine and remote monitoring tools have seen a growth in demand as hospitals focus on keeping patients safe while delivering care.

Diagnos Client Signings Continue

Recent client successes have included:

  • Last month, Diagnos announced a contract with Devlyn Grupo, an optical retailer with over 900 stores in Mexico and Guatemala. Devlyn will test the CARA platform for diabetic retinopathy screening at select locations with a planned larger roll out to more stores in early 2021.
  • In September, Diagnos reported that it re-signed a U.S.-based client, Chaparral Medical Group, to another three-year agreement. Chaparral is a 60 physician multi-specialty group serving 23 clinics in Southern California.
  • In July, Diagnos signed a service agreement with the Colombian Telemedicine Centre Ltd (“CTMC”) in Colombia, South America. The CTMC selected the CARA platform to start screening Colombia’s population in conjunction with largest vision specialist center in the country.
  • In June, Diagnos executed an agreement with Labtician Ophthalmics, a Toronto-based surgical eye care products and equipment company with customers across Canada, and Labtician will use Diagnos’AI solution to monitor ocular health in its diabetic patients.

Well Funded for Growth

Diagnos is well funded after raising $2.1M in capital earlier this year and then receiving a $2M, 10-year, interest-free loan from the government of Quebec via the Economic Development Fund to support the commercialization of the CARA platform globally.

The CARA platform is securely accessible over the Internet and Diagnos currently operates screening sites in 15 countries with certifications from regulatory bodies in various countries including the U.S., Canada, the European Union, and Mexico.

Meanwhile, even after Diagnos’ recent stock jump, the Company’s market capitalization is only $32.5M and makes it a prime takeover target for any consolidator executing a roll-up strategy in the healthtech industry.

Michael Lende on a Health Canada approved touchless fever detection system that can help identify potential at-risk carriers

Peter Clausi with Predictiv AI CEO Michael Lende on the touchless ThermalPass Fever Detection System

In a recent InvestorIntel interview Peter Clausi speaks with Michael Lende, President and CEO of Predictiv AI Inc. (TSXV: PAI), about their ThermalPass Fever Detection System. Michael said that ThermalPass is a Health Canada approved touchless fever detection system that can help identify potential at-risk carriers.

In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Michael went on to say that camera-based sensors have privacy issues but Predictiv AI’s ThermalPass Fever Detection System uses thermal medical grade sensors which are nonintrusive and preserves anonymity of the people passing through. “It can scan 60 people per minute.” He added. “There are 24 medical grade sensors in the ThermalPass, each taking 100 readings per second. It is quite accurate as you are going through.” To watch the full interview, click here

About Predictiv AI:

Predictiv AI Inc. is a technology company which helps businesses and organizations make smarter decisions using advanced artificial intelligence, deep machine learning and data science techniques. Its Weather Telematics Inc. subsidiary uses patented air quality monitoring sensors to provide predictive weather risk information to the insurance, logistics, fleet management and public safety sectors. The Company’s R&D division, AI Labs Inc., develops new products that solve real-world business problems. The joint venture with Commersive Solutions Corp. is developing innovative technologies for use in various public spaces, starting with the ThermalPass™ fever detection system. To learn more about Predictiv AI Inc., click here

Disclaimer: Predictiv AI Inc. is an advertorial member of InvestorIntel Corp.

Predictmedix is starting to commercialize as AI health screening & monitoring takes off

Health screening is big business these days. The latest way is using Artificial Intelligence (AI) to mass screen and/or monitor for impairment and various disease states, including COVID-19.

One company is now starting to commercialize their technology, winning contracts and forming distribution partners all around the globe. That company is Predictmedix Inc. (CSE: PMED | OTCQB: PMEDF).

The global market size for AI in healthcare in 2017 was US$1.4b and is forecast to rise to reach US$28b by 2025, for an approximate 20 fold increase in just 8 years. Healthcare screening and monitoring using AI can play a key role.

The global market for artificial intelligence (AI) in healthcare is forecast to take off


Predictmedix has developed leading disruptive AI technology in impairment detection and healthcare screenings. Their AI powered products use facial, thermal, video and audio recognition technologies to determine when individuals are suffering from infectious disease, are drug or alcohol impaired, or have a mental illness. The Predictmedix screening devices are backed up by a remote patient monitoring platform.


Predictmedix’s latest achievements to commercialize their screening AI technology

  • October 1, 2020 – Partnered with Versus Systems to develop tools for clinical trials, in particular on-site monitoring to ensure human subject protection, data integrity, and quality. The news release states: “This will allow Predictmedix to enter a new industry vertical of clinical trials which is a $40 billion market opportunity as estimated by Fortune Business Insights.”
  • September 3, 2020 – Predictmedix Inc. and Juiceworks Exhibits provide safe entry solutions to facility managers at IFMA World Workplace in Texas.
  • August 17, 2020 – Predictmedix Inc. and Juiceworks Exhibits announce COVID-19 technology deployments in North America.
  • August 12, 2020 – Deployment of Impairment Screening along with COVID-19 symptom screening technology at Indian Oil Corporation.
  • July 7, 2020 – Sales/distributor 1 year contract with Taurus Medical in the United Kingdom. Taurus Medical manufacture and market over 1,500 products for the diagnosis, treatment and monitoring of respiratory conditions. They are a supplier for the UK National Health Service. Taurus is offering Predictmedix COVID-19 mass screening entry modules to the healthcare, retail, and the entertainment sector in the UK.
  • June 26, 2020 – Teamed up with Tech Mahindra who will resell Predictmedix to their global client base. Tech Mahindra is a $4.9 billion dollar company owned by Mahindra Group. Tech Mahindra is operational across 90 countries, helping 973 global customers including Fortune 500 companies.

Regarding the Indian Oil Corporation contract Predictmedix state:

“The deployment of our COVID-19 screening and impairment technology at IOCL which is a fortune 500 company marks our entry into the Oil & Gas sector which is one of the largest industrial sectors and it further highlights the market need for the suite of technologies developed by Predictmedix.”

Now that’s a very busy past 5 months. The model of using well known brands (Juiceworks Exhibits, Taurus Medical, Tech Mahindra) with large distribution networks should make for a faster and more successful commercialization. Product deployment at large corporations such as Indian Oil Corporation show solid early demand for the Predictmedix product.

Predictmedix operates under a SaaS model. Clients pay a monthly fee based on tiered volume of screenings or by number of device feeds. Both pricing options provide Predictmedix with recurring monthly revenue and multi-year contracts.

Right now as COVID-19 cases approach 40 million (and 1.2 million deaths) it certainly looks like there is a massive potential market for Predictmedix’s COVID-19 Safe Entry Solutions. This could be the product that rapidly launches Predictmedix into the AI health screening market. You can read more on that here.

Predictmedix current market cap is C$58m. The Company looks to have plenty of growth opportunities ahead as it strives to capture a share of the forecast US$28b AI healthcare market by 2025.

Further learning

Predictiv AI debuts real-world problem solver, a fever detection system called ThermalPass

“If you can predict the future, you can profit from it…”

All you good capitalists out there should be salivating at that comment. It’s from the homepage of Predictiv AI Inc. (TSXV: PAI | OTC: INOTF | FRANKFURT: 71TA) and as you may have surmised, their business is the business of artificial intelligence (AI). Predictiv AI “is a technology company which helps businesses and organizations make smarter decisions using advanced artificial intelligence, deep machine learning and data science techniques.”

The global AI market is expected to grow in leaps and bounds – by as much as 40-50% per year – in the next decade or so. This makes it a market that could be in the trillions of dollars – there is money to be made and Predictiv AI is positioned to be a part of that. End users of AI include almost anything – the automotive industry (self-driving vehicles especially), the healthcare industry, banking, finance, insurance, manufacturing and agriculture to mention just a few that are important in our daily lives.

Predictiv AI has two subsidiaries – AI Labs (the R&D arm of the company) and Weather Telematics. As big as the AI market is (think the “Internet of Things”), the team’s deep experience was in part responsible for the company’s current focus.

AI Labs uses proprietary artificial intelligence to build solutions for the public safety and security markets, a subsector that is projected to reach more than US$900 billion by 2027 and is part of a larger overall sector that also includes energy management, smart buildings, mobility, technology, infrastructure, and healthcare, which are expected to total US$1.56 trillion by 2025.

AI Labs is currently building solutions for real-world problems and has successfully developed a patent-pending fever detection system (ThermalPass). Since the start of the coronavirus pandemic, the way the world now operates will be forever changed. As announced earlier in October, Predictiv AI, via a joint venture with Commersive Solutions Corp., has transitioned from the prototype phase into the commercialization phase. An Ontario Canada-based trucking company was the first to deploy the system commercially on October 13, 2020.

The ThermalPass Fever Detection System detects body temperature using multiple touchless, infrared, thermal medical grade sensors to identify potential at-risk carriers. The device is efficient and can process up to 60 people per minute without any need for people to do anything but walk normally through the sensor system. It is approved by Health Canada as a class 1 medical device and is a critical real-time detector that can help companies everywhere in the fight against the spread of the coronavirus. The uses for this product are everywhere that people go in public and the market is massive.

ThermalPass is arguably the best, most effective and simplest temperature scanning system available. It is also the least expensive, when compared to competitors in China and the US and has a patent pending. Currently made in Canada, it is easy to assemble, there are stationary and mobile versions available, and the company has secured leading Canadian and US suppliers to contract manufacture the units. Also, ThermalPass has the supply chain in place to rapidly scale production to meet demand. Notably, the US government has put a ban on Chinese thermal-camera based systems, limiting competition to the ThermalPass system particularly in the US.

Temperature scanners will probably become a fact of life – the ability to provide a better mousetrap such as the ThermalPass product, means that the world should beat a path to company’s door, based on ease of use, reliability of the technology and lower than average price.

The second significant product line comes from the Weather Telematics subsidiary. The company has a product called “Alert Fleet”, which uses advanced AI and deep machine learning to generate hyper-local advanced road weather data using Weather Telematics patented sensors. This is a critical piece of technology that could save the trucking industry significant time (and money) by being to avoid serious weather conditions, winter and summer.

Alert Fleet can generate real-time road alerts 200-300 meters ahead, 1 km ahead and 100s of kilometers in advance of hazardous road conditions and can provide up to 72 hour advanced proprietary predictive weather data using patented AI and sensor technology. It can alert to winter conditions (snow, ice, black ice), hydroplaning/flooding risk, low visibility (fog) risk as well as wind, hail and lightening risks. It can be a standalone product, can be integrated into existing telematics service provider portals and can be delivered inside the vehicle as well as to a dispatcher via text messaging, email or mobile app integrations.

The company has a market capitalization of approximately C$19.5 million and just completed a share consolidation in August 2020, along with the changing of the company’s name to Predictiv AI Inc. (previously Internet of Things Inc.). The company has a small amount of debt ($311,000) mostly in the form of a demand loan, but in early October 2020 closed a nonbrokered private placement of $1.5 million primarily to fund the ThermalPass production planning and manufacturing as well as providing capital to AI Labs for ongoing R&D. While it is still early days for investors in this company, there appears to be a particularly bright future ahead in an ever changing world.

Boosting electric vehicles with artificial intelligence and leadership, a powerful combination for Exro Technologies

Two of the biggest trends this decade are electric vehicles (EVs) and artificial intelligence (AI). Together they make a powerful combination. Just take a look at the chart below for Exro Technologies Inc. (CSE: XRO | OTCQB: EXROF) (“Exro”). Exro’s stock price is up over 400% in the past year, which coincides with the time that CEO Sue Ozdemir has been with the company.

Exro Technologies (CSE: XRO) stock price is up 413% over the past 1 year


Exro Technologies is a software design technology and smart energy company that creates a software module called a “Coil Driver” that uses AI to make electric motors function better. In an electric car, the Coil Driver acts like gears do on a conventional car, boosting an EV motor’s range and performance by using two separate torque profiles for a motor. The first is calibrated for low speed and high torque, while the second provides expanded operation at high speed.

Reflecting on the past year and why Exro has done so well

Over the past year Exro has made very significant steps in commercializing their technology, securing several significant partnerships along the way. Here is a brief summary of Exro’s partners/agreements:

  • SEA Electric Pty Ltd. – In July 2020, Exro announced a partnership to enhance electric powertrain technology for heavy-duty trucks and delivery vehicles.
  • Zero Motorcycles (“Zero”) – In June 2020, Exro announced a collaboration agreement with Zero to evaluate Exro’s patented Coil Drive technology using Zero’s SR/S powertrain platform. Zero is a big name in electric motorbikes.
  • Clean Seed Capital Group Ltd. – On April 28, 2020, Exro announced it has signed a collaboration and supply agreement with Clean Seed Capital Group Ltd. (TSX-V: CSX) to integrate Exro’s technology into Clean Seed’s high-tech agricultural seeder and planter platforms, advancing the electrification of the world’s heavy-farm equipment.
  • Motorino Electric – In December 2019, Exro partnered with Motorino Electric. Exro’s engineered technology provided a torque and acceleration increase of 25% for the Motorino e-bike.
  • Templar Marine – Exro has a pilot project running with Templar Marine’s water taxis. The marine sector is a multi-billion dollar industry that can stand to benefit enormously from Exro’s technology as they increasingly switch across to electric motors for a cleaner environment.
  • Aurora Powertrains – Exro has partnered with Aurora to improve the Aurora’s all-electric snowmobile.
  • Potencia Industrial – Exro has contracts with Potencia Industrial, which is one of Mexico’s leading motor manufacturers. Potencia designs and manufactures special application, high efficiency, electrical motors and generators. One of their projects involves converting internal combustion engines in Mexico City’s taxis to electric motors, as part of a city-wide initiative to green the city’s 250,000 taxi fleet. Exro works to integrate its hardware and software technology into Potencia’s motor drives. The Exro customized driver will be used as the inverter for Potencia’s Pronto Power Flexible Powertrain.

“It’s hard to believe that is has been a year since I joined Exro,” said Exro CEO Sue Ozdemir. “The past 12 months has been so rewarding as we innovate and transform our business. We are positioning ourselves to become leaders as we use the power of our technology to transform the way the world looks at energy consumption. I believe we now have the ideal platform to be successful.” As for future plans, Ozdemir said: “Our team is continuing to focus our attention on co-development with our partnerships. We have a strong pipeline and are optimistic in our ability to meet our commitment to eight deals by the end of 2020. Further, we are gaining global presence as our partners deliver applications in North America, Australia, and Europe.”

As most experienced investors know it is one thing to have a good idea or product, but it is another thing to successfully market, commercialize, and make profits. Exro is already doing the first two, and revenue is forecast to soon follow in 2021, growing in 2022.

Exro Technologies financials and forecast financials



In a September corporate update Exro set out the following near term events for the company:

“November 2020 – Delivery to Potencia (electric car application). This is an especially pivotal project for Exro as it will become the platform design, reducing design time for future partnerships. It also serves as our first in-car application, demonstrating our ability to transform the automotive power electronics industry.

December 2020 – the IBMS (Intelligent Battery Management System) proof of concept. With the research phase now behind us, this technology development will allow us to provide test bench data to support our simulations and confirm that we are able to provide a solution for first life batteries to be used in second life applications, such as stationary storage for example.

Q4 2020 – We expect the 8th deal will be yet another representation of the versatility and scope of our innovation. We put a lot of effort into how each partnership contributes towards our future growth plan. Finding partners that deliver a new segment, new geography or new application is part of securing our footprint in many market segments. This will position us for a robust and sustainable future.

Early 2021 (Q1) – Delivery to Zero Motorcycle (“Zero”) (electric motorcycle application).”

Closing remarks

There is no doubt that Exro Technologies has had a busy year. Their technology is clearly being very well received by the market and the steps to commercialize the technology are now being put in place. When we consider the massive size of the electric motor market, in particular the new and surging demand for EVs, it is not surprising when Exro CEO Sue Ozdemir says “we have a lot of room for growth”. I think that is a huge understatement.

For their investors it has been a great year. Given that Exro trades on a market cap of just C$114m, if they succeed in the next step of rapidly raising revenues, this could be just the beginning.  I will be very interested to see how Exro Technologies goes over the year ahead.

Predictmedix’s Dr. Rahul Kushwah on using AI to solve real world problems

Using artificial intelligence to mass screen for COVID-19

“It’s about the different verticals that we are addressing with Predictmedix,” says Dr. Rahul Kushwah, Co-Founder and COO of Predictmedix Inc. (CSE: PMED | OTCQB: PMEDF). “We are an artificial intelligence company and we are solving real-world problems.”

In an interview with InvestorIntel’s Tracy Weslosky, Dr.  Kushwah explains three of their vertical markets: “COVID-19 pandemic, we are all in the midst of it and we have a technology which is to mass screen for COVID-19. Similarly, impairment is a big issue when it comes to workplace and law enforcement and we have a solution for that. And the third vertical is mental illnesses. $300 billion spent in the US last year and there is so much subjectivity that goes into diagnosis and we are developing a solution to diagnose mental illnesses.”

“We have developed modules which look like metal detectors,” Dr.  Kushwah continued. “You walk through these modules and on the other end you have a green or red light. If someone is identified to be positive for COVID-19 symptoms a red light goes off – if not then you get a green light.” He continued, “it is a tool that you can use for mass screening in airports, transit hubs, malls, office building, government buildings, or anywhere you can imagine where you have big flow of people.” Dr. Kushwah also discusses the pitfalls of current telehealth and telemedicine platforms, and Predictmedix’s innovative solutions.

To access the complete interview, click here

Disclaimer: Predictmedix Inc. is an advertorial member of InvestorIntel Corp.

Predictmedix’s Dr. Kushwah on how AI technology for mass screening of COVID-19 is here

“We have developed a technology to screening for COVID-19 and the key is, it is a mass screening technology. The technology works with multispectral imaging and our AI algorithms, which are patent pending and sit on a cloud, and they communicate directly with the multispectral cameras. These cameras can be installed and as people are passing by, the technology will just screen them for COVID-19.” States Dr. Rahul Kushwah, Co-Founder and COO of Predictmedix Inc. (CSE: PMED | OTCQB: PMEDF), in an interview with InvestorIntel’s Tracy Weslosky.

Dr. Kushwah went on to say that the technology can be deployed in places where there is movement of large number of people like airports, shopping centers, malls, arenas, transit hubs, etc. He added, “If you want to control the next wave you have to ensure that there is no transmission of infection and the only way you can do that is by containment and to contain you have to identify.”

Dr. Kushwah also provided an update on the appointment of Microsoft Director of Business Development for AI solutions, Kapil Raval, as the Chairman of the Advisory Board. He said that Predictmedix is working very closely with the Indian Institute of Technology to scale up its technologies. Dr. Kushwah also said that Predictmedix has deployed its mass screening technology for COVID-19 with Max Healthcare. He continued, “Max Healthcare is one the largest healthcare group in South Asia…They have 14 hospitals with over 3000 doctors, and we have deployed our technology at their facilities. That is a phenomenal validation to what we have developed.”

To access the complete interview, click here

Disclaimer: Predictmedix Inc. is an advertorial member of InvestorIntel Corp.

The Perfect Market Storm: Critical Materials, Cleantech and COVID-19

There seems to be a misguided notion (with some) that isolation means we have more time to waste. Far from reality, I am certain that many of you, like me are looking at your inbox wondering where or how to wade into the depth of quality deals and opportunities upon us…

Would like to kick your morning coffee off with a special nod to our longstanding friends from Avalon Advanced Materials Inc. (TSX: AVL | OTCQB: AVLNF) whose $AVL soared 50% yesterday. We have been supporters of #Avalon since Don Bubar first did an interview with me in 2009 (with Jack Lifton) and introduced me to rare earths. And indeed, there is news flow in the rare earths a-n-d throughout the critical materials sector that is literally ricocheting from source-to-source online…

How to follow?

Jack Lifton, Clint Adam Smyth and I just launched the TechnologyMetals.com site to manage the influx of critical materials’ news (and experts) we are communicating with regularly. Jack’s interview with Dr. David Dreisinger on Search Minerals Inc. (TSXV: SMY) last week was purely outstanding (in my opinion) as he describes David as “the leading authority on solvent extraction process”. This is a hot topic that we touch on in our weekly update that we just started…click here to access a preview

And associated technologies relating to cleantech? We saw Exro Technologies Inc. (CSE: XRO | OTCQB: EXROF) stock move up 30% yesterday! Interviewing CEO Sue Ozdemir on how Exro makes “electric motors faster, stronger and greener” for InvestorIntel on Wednesday: we will get this up live as fast as we can!

Uranium continues to maintain a much-deserved interest, let me point you in the right direction for a quick update – Matt Bohlsen’s piece from last week titled, The DoE’s plan to rebuild the uranium sector and ‘pull America’s nuclear industrial base back from the brink of collapse’… reinforces the sustainability themes we are touting on the Technology Metals Show. Arranging interviews as we speak with Mark Chalmers of Energy Fuels Inc. (NYSE: UUUU | TSX: EFR) and Jeff Klenda of Ur-Energy Inc. (NYSE: URG | TSX: URE) as they “stand to be the major beneficiaries, especially given they started the whole S232 petition back in January 2018” you should see those live on InvestorIntel next week.

And yes, we are following the biotech and life sciences market. If you subscribe to our AI driven market updates on InvestorChannel.com – you can catch the 20 companies, we are following in the race for vaccinations…click here

Speaking of AI technology, we would like to ensure that you are aware of the news that was put out by Predictmedix Inc. (CSE: PMED | OTCQB: PMEDF) yesterday titled — Predictmedix Files Patent for Mass Screening for Infectious Diseases Such As #COVID19

1 YR stock Chart for Predictmedix Inc. (CSE: PMED) – Source: TD Waterhouse

And speaking on the war against the COVID-19, StageZero Life Sciences Ltd. (TSX: SZLS) put out the following news on April 20th StageZero Life Sciences Initiates Testing for COVID-19 In the USA

Remember, click here to subscribe to the InvestorChannel for daily market updates on the Canadian, US and Hong Kong markets – and to follow InvestorIntel’s stock watchlist for Gold, Uranium, Rare Earths and of course, COVID-19…